Reaction
Arthritis Enteropathic reporting signals
As of the last recalculation, Arthritis Enteropathic appears in 324 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is VEDOLIZUMAB (PRR 59.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vedolizumab | 64 | 59.2 | 59.3 |
| Adalimumab-Fkjp | 33 | 50.8 | 50.9 |
| Adalimumab-Adaz | 37 | 50.7 | 50.8 |
| Adalimumab-Aaty | 33 | 49.8 | 49.8 |
| Ustekinumab | 33 | 22.9 | 23.0 |
| Isotretinoin | 16 | 21.8 | 21.8 |